Cost-effectiveness analysis at the development phase of a potential health technology: Examples based on tissue engineering of bladder and urethra

Journal of Tissue Engineering and Regenerative Medicine

Volumn 1, Issue 5, 2007, Pages 343-349

  McAteer, Helen ^a   Cosh, Emma ^a   Freeman, Guy ^a   Pandit, Anand ^a   Wood, Peter ^a   Lilford, Richard ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Bladder; Cost effectiveness; Cost effectiveness gap; Headroom method; QALY; Regenerative medicine; Tissue engineering; Urethra

Indexed keywords

COST BENEFIT ANALYSIS; COST ENGINEERING; COSTS; INVESTMENTS; REGENERATIVE MEDICINE; TISSUE; TISSUE ENGINEERING;

BLADDER; COST EFFECTIVENESS ANALYSIS; COST-EFFECTIVENESS GAP; DEVELOPMENT PHASIS; HEADROOM METHOD; HEALTH ECONOMICS; QALY; REGENERATIVE MEDICINE; TISSUES ENGINEERINGS; URETHRA;

COST EFFECTIVENESS;

ARTICLE; BLADDER; BLADDER TUMOR; CONGENITAL MALFORMATION; COST BENEFIT ANALYSIS; CYTOLOGY; DECISION SUPPORT SYSTEM; ECONOMICS; HUMAN; MEDICAL TECHNOLOGY; METHODOLOGY; REGENERATIVE MEDICINE; STATISTICS; TISSUE ENGINEERING; TRANSPLANTATION; TREATMENT OUTCOME; URETHRA; UROTHELIUM;

BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; REGENERATIVE MEDICINE; TISSUE ENGINEERING; TREATMENT OUTCOME; URETHRA; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 34848860560     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.36     Document Type: Article

References (54)

1. Ades AE, Lu G, Claxton K. 2004; Expected value of sample information calculations in medical decision modelling. Med Decision Making 24: 207-227.
2. Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB. 2006; Tissueengineered autologous bladders for patients needing cystoplasty. Lancet 367: 1241-1246.
3. Atala A, Freeman MR, Vacanti JP, Shepard J, Retik AB. 1993; Implantation in vivo and retrieval of artificial structures consisting of rabbit and human urothelium and human bladder muscle. J Urol 150: 608-612.
4. Barbagli G, Palminteri E, Lazzeri M, Guazzoni G. 2003; Anterior urethral strictures. BJU Int 92: 497-505.
5. Bhargava S, Chapple CR. 2004; Buccal mucosal urethroplasty: is it the new gold standard? BJU Int 93: 1191-1193.
6. Bouchie A. 2002; Tissue engineering firms go under. Nat Biotechnol 20: 1178-1179.
7. Brannan W, Ochsner MG, Fuselier HA Jr, Landry GR. 1978; Partial cystectomy in the treatment of transitional cell carcinoma of the bladder. J Urol 119: 213-215.
8. Couvelaire R. 1951; Cysto-enteroplasty for the small, tuberculous bladder. J Urol Med Chir 57: 530-532.
9. Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ. 1999; Epidemiology of interstitial cystitis: a population based study. J Urol 161: 549-552.
10. Department of Health. 2006; NHS Reference Costs 2005-2006. Department of Health: London, UK.
11. Devlin N, Parkin D. 2004; Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13: 437-452.
12. Dublin N, Stewart LH. 2004; Oral complications after buccalmucosal graft harvest for urethroplasty. BJU Int 94: 867-869.
13. Duel BP, Gonzalez R, Barthold JS. 1998; Alternative techniques for augmentation cystoplasty. J Urol 159: 998-1005.
14. Faysal MH, Freiha FS. 1979; Evaluation of partial cystectomy for carcinoma of bladder. Urology 14: 352-356.
15. Fichtner J, Filipas D, Fisch M, Hohenfellner R, Thuroff JW. 2004; Long-term outcome of ventral buccal mucosa onlay graft urethroplasty for urethral stricture repair. Urology 64: 648-650.
16. Freeman G, Lilford R, Pandit A, Wood P. 2006; Methods of eliciting the utility of the clinical effects of cystoplasty and urethroplasty. http://www.pcpoh.bham.ac.uk/publichealth/nccrm/healtheconomicsandstatistics.htm.
17. Greenwell TJ, Venn SN, Mundy AR. 2001; Augmentation cystoplasty. BJU Int 88: 511-525.
18. Harper M, Fowler CJ, Dasgupta P. 2004; Botulinum toxin and its applications in the lower urinary tract. BJU Int 93: 702-706.
19. Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P. 2003; A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92: 325-326.
20. Hasan ST, Marshall C, Robson WA, Neal DE. 1995; Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. Br J Urol 76: 551-557.
21. Hayter CR, Paszat LF, Groome PA, Schulze K, Mackillop WJ. 2000; The management and outcome of bladder carcinoma in Ontario, 1982-1994. Cancer 89: 142-151.
22. Henze T. 2005; Managing specific symptoms in people with multiple sclerosis. Int MS J 12: 60-68.
23. HES Online. 2007; Hospital Episode Statistics 2005-2006: http://www.hesonline.nhs.uk.
24. Ivil KD, Suresh G. 2002; Review of augmentation 'clam' cystoplasy in a district general hospital setting. Int Urol Nephrol 34: 129-132.
25. Jamison J, Maguire S, McCann J. 2004; Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004375/pdffs.html.
26. Jardin A, Vallancien G. 1984; Partial cystectomy for bladder tumours. Prog Clin Biol Res 162A: 375-385.
27. Kropp BP, Eppley BL, Prevel CD, et al. 1995; Experimental assessment of small intestinal submucosa as a bladder wall substitute. Urology 46: 396-400.
28. Kropp BP, Rippy MK, Badylak SF, et al. 1996; Regenerative urinary bladder augmentation using small intestinal submucosa: urodynamic and histopathologic assessment in long-term canine bladder augmentations. J Urol 155: 2098-2104.
29. Levine J, Wessells H. 2001; Comparison of open and endoscopic treatment of posttraumatic posterior urthral strictures. World J Surg 25: 1597-1601.
30. Merrell RW, Brown HE, Rose JF. 1979; Bladder carcinoma treated by partial cystectomy: a review of 54 cases. J Urol 122: 471-472.
31. Milsom I, Abrams P, Cardozo L, et al. 2001; How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87: 760-766.
32. Mingin GC, Baskin LS. 2003; Surgical management of the neurogenic bladder and bowel. Int Braz J Urol 29: 53-61.
33. North American Association of Central Cancer Registries. 2006; Cancer Incidence Data: http://www.naaccr.org/cinap/index.htm.
34. Oberpenning F, Meng J, Yoo JJ, Atala A. 1999; De novo reconstitution of a functional mammalian urinary bladder by tissue engineering. Nat Biotechnol 17: 149-155.
35. Office for National Statistics. 2005; Registrations of Cancer Diagnosed in 2002, England. Office for National Statistics: London.
36. Ojeda L, Johnson DE. 1983; Partial cystectomy: can it be incorporated into integrated therapy program? Urology 22: 115-117.
37. Piechota HJ, Dahms SE, Nunes LS, et al. 1998a; In vitro functional properties of the rat bladder regenerated by the bladder acellular matrix graft. J Urol 159: 1717-1724.
38. Piechota HJ, Dahms SE, Probst M, et al. 1998b; Functional rat bladder regeneration through xenotransplantation of the bladder acellular matrix graft. Br J Urol 81: 548-559.
39. Probst M, Dahiya R, Carrier S, Tanagho EA. 1997; Reproduction of functional smooth muscle tissue and partial bladder replacement. Br J Urol 79: 505-515.
40. Probst M, Piechota HJ, Dahiya R, Tanagho EA. 2000; Homologous bladder augmentation in dog with the bladder acellular matrix graft. BJU Int 85: 362-371.
41. Radziszewski P, Borkowski A. 2002; Botulinum toxin type A intravesical injections for intractable bladder overactivity. Eur Urol Suppl 1: 134.
42. Reitz A, Stohrer M, Kramer G, et al. 2004; European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510-515.
43. Rivera I, Wajsman Z. 2000; Bladder-sparing treatment of invasive bladder cancer. Cancer Control 7: 340-346.
44. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. 2005 The economic consequences of prostate and bladder cancer in the UK. BJU Int 95: 59-63.
45. Schultheiss D, Bloom DA, Wefer J, Jonas U. 2000; Tissue engineering from Adam to the zygote: historical reflections. World J Urol 18: 84-90.
46. Schurch B, Stohrer M, Kramer G, et al. 2000; Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692-697.
47. Stonehill WH, Dmochowski RR, Patterson AL, Cox CE. 1996; Risk factors for bladder tumors in spinal cord injury patients. J Urol 155: 1248-1250.
48. Sutherland RS, Baskin LS, Hayward SW, Cunha GR. 1996; Regeneration of bladder urothelium, smooth muscle, blood vessels and nerves into an acellular tissue matrix. J Urol 156: 571-577.
49. Ubel PA, Loewenstein G, Jepson C. 2003; Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 12: 599-607.
50. Utz DC, Schmitz SE, Fugelso PD, Farrow GM. 1973; Proceedings: a clinicopathologic evaluation of partial cystectomy for carcinoma of the urinary bladder. Cancer 32: 1075-1077.
51. Vaught JD, Kropp BP, Sawyer BD, et al. 1996; Detrusor regeneration in the rat using porcine small intestinal submucosal grafts: functional innervation and receptor expression. J Urol 155: 374-378.
52. Venn SN, Mundy AR. 2000; 'Nerve-sparing' cystectomy in women. Int Urogynecol J Pelvic Floor Dysfunct 11: 237-240.
53. Venn SN, Popert RM, Mundy AR. 1998; 'Nerve-sparing' cystectomy and substitution cystoplasty in patients of either sex: limitations and techniques. Br J Urol 82: 361-365.
54. WHO (World Health Organization). 2006; Schistosomiasis: http://www.who.int/immunization/topics/schistosomiasis/en/index.html.